Irbesartan Medical Valley

Irbesartan, the active ingredient in Irbesartan Medical Valley, is an Angiotensin II receptor blocker (ARB) presented as an oral dosage form for oral use. It treats hypertension and diabetic nephropathy in adult patients.

GNH USA supplies Irbesartan Medical Valley as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Irbesartan belongs to the class of Angiotensin II receptor blockers and is used to manage conditions related to the renin‑angiotensin system.

Hypertension: lowers elevated blood pressure and reduces cardiovascular risk. Diabetic nephropathy: slows the progression of kidney damage in patients with type 2 diabetes.

Common Side Effects: - Dizziness or light‑headedness. - Headache. - Fatigue. - Nausea. - Elevated potassium levels. - Mild hypotension.

Serious or Rare Side Effects: - Angioedema or severe swelling. - Acute renal failure. - Hepatic injury. - Severe hypotension. - Allergic reactions such as rash or hives. - Hyperkalemia leading to cardiac arrhythmia.

Before initiating therapy, consider the following precautions: - Monitor blood pressure regularly to assess therapeutic response. - Check renal function and serum creatinine at baseline and periodically. - Monitor serum potassium, especially in patients on potassium‑sparing diuretics or supplements. - Use with caution in pregnancy; Irbesartan is classified as Category D. - Avoid in patients with severe hepatic impairment. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Irbesartan may interact with several medicines, requiring attention to dosing and monitoring.

Major Interactions (Avoid): - Concomitant use with aliskiren in diabetic patients. - Combination with ACE inhibitors or other ARBs (risk of hyperkalemia and renal impairment). - Use with potassium‑sparing diuretics (increased potassium levels). - Co‑administration with NSAIDs (potential renal function decline).

Moderate Interactions (Monitor Closely): - Lithium (increased lithium levels). - Other antihypertensives (additive blood pressure lowering). - Cyclosporine or tacrolimus (enhanced nephrotoxicity).